模块化人工心脏瓣膜体外脉动流测试方法研究OACSTPCD
In Vitro Measurement of Pulsatile Flow Test Method of Modular Artificial Heart Valves
目的 基于ISO 5840和GB 12279标准对人工心脏瓣膜体外脉动流性能测试设备的要求,探索一种测试数据可靠、稳定的模块化人工心脏瓣膜体外脉动流测试模型.方法 利用模块化组件分别搭建主动脉瓣脉动流测试模型A和二尖瓣脉动流测试模型B,将25AJ-501型和25MJ-501型美国圣犹达瓣膜分别安装在对应模型上进行瓣膜体外脉动流试验;对测试结果进行独立样本t假设检验,评估瓣膜在模型A和模型B上的测试结果可靠性;在模型A和模型B上分别交换测试瓣位置和变化前向流百分比(Forward Flow Duration,FFD)进行瓣膜脉动流测试,记录对比分析所得数据,研究测试条件改变前后对模型测试结果的影响;将23A、25A、29A CL-V型瓣膜安装在模型A上,将23M、25M、29M CL-V型瓣膜安装在模型B上,在健康、运动、心衰生理条件下,研究CL-V型瓣膜脉动流性能参数平均跨瓣压差(Mean Pressure Gradient,MPG)、有效瓣口面积(Effective Orifice Area,EOA)、反流百分比(Regurgitant Fraction,RF)的变化.结果 瓣膜在模型A和模型B下监测得到的脉收缩压、动脉舒张压、平均主动脉压、脉动流压力和流量波形图符合GB 12279-2008/ISO5840:1996标准要求;当25AJ-501型主动脉瓣在模型B上测瓣位置时,EOA值偏小5.1%,RF值偏小22.4%,当25MJ-501型二尖瓣装在模型A上测试瓣位置时,EOA值偏小7.5%,RF值偏大23.3%,交换测试瓣位置后差异性显著;瓣膜在FFD控制条件增大后,正压差期间的前向流均方根和MPG值均减小,FFD对模型A、模型B瓣膜EOA测试结果有影响;不同规格CL-V型瓣膜在该模型下运行时,相同生理条件下,MPG、EOA、RF的变化与测试模型无关,只受瓣膜尺寸影响;在3种不同生理条件下,脉动流MPG、EOA、RF的变化受瓣膜尺寸和生理条件影响,测试结果呈现规律性变化.结论 这种模块化体外脉动流测试模型符合ISO 5840和GB 12279标准对人工心脏瓣膜体外脉动流测试的设备要求,可作为国产人工心脏瓣膜体外脉动流性能测试模型的一种参考方案.
Objective Based on the requirements of ISO 5840 and GB 12279 standards for in vitro pulsatile flow performance testing equipment of artificial heart valves,to explore a modular in vitro pulsatile flow testing model for artificial heart valves with reliable and stable test data.Methods Modular components were utilized and separate models of aortic valve pulsatile flow test A and mitral valve pulsatile flow test B were constructed.The 25AJ-501 and 25MJ-501 America St.Jude Medical valves were respectively installed on the corresponding models for in vitro pulsatile flow test of the valves.The test results were subjected to independent sample t-test hypothesis testing to evaluate the reliability of the valve test results in models A and B.Valve pulsation flow test was performed on model A and model B by exchanging test valve positions and changing forward flow duration(FFD),and the data obtained were recorded for comparative analysis to study the influence of test conditions on model test results before and after the change.The 23A,25A,and 29A CL-V valves were mounted on model A,and the 23M,25M,and 29M CL-V valves were mounted on model B.The changes in the pulsatile flow performance parameters of the CL-V valves,including mean pressure gradient(MPG),effective orifice area(EOA),and regurgitant fraction(RF)were studied,under healthy,exercise,and heart failure physiological conditions.Results The pulse systolic pressure,arterial diastolic pressure,mean aortic pressure,pulsatile flow pressure and flow rate waveforms of the valves monitored under model A and model B were in accordance with the requirements of GB 12279-2008/ISO 5840:1996.When type 25AJ-501 aortic valve was located in model B,the EOA value and the RF were decreased by 5.1% and 22.4%,respectively.While the type 25MJ-501 mitral valve was located in model A,the EOA value was decreased by 7.5% and the RF value was increased by 23.3%,and the difference was significant after the test valve position was exchanged.With the increase of FFD control condition,the root mean square of forward flow and MPG value decreased during the positive pressure difference period.FFD had influence on the EOA test results of model A and model B valves.When CL-V valves of different specifications were operated under this model,the changes of MPG,EOA and RF under the same physiological conditions had nothing to do with the test model,but were only affected by valve size.Under three different physiological conditions,the changes of MPG,EOA and RF were affected by valve size and physiological conditions,and the test results showed regular changes.Conclusion This modular in vitro pulsatile flow test model meets the equipment requirements of ISO 5840 and GB 12279 standards for in vitro pulsatile flow testing of artificial heart valves and can be used as a reference for the in vitro pulsatile flow test model of domestic artificial heart valves.
杨英;陈大雷;刘丽;刘璐;史永亮;康华;魏周华;李清浣
甘肃省医疗器械检验检测所,甘肃 兰州 730030中国食品药品检定研究院,北京 102600兰州兰飞医疗器械有限公司,甘肃 兰州 730030上海心瓣测试设备有限公司,上海 200120
预防医学
人工心脏瓣膜脉动流性能测试模型有效瓣口面积反流百分比
artificial heart valveperformance test of pulsating flowmodelseffective flap opening areapercentage of reflux
《中国医疗设备》 2024 (007)
20-27,35 / 9
甘肃省药品监督管理局科学技术类项目(2022GSMPA0033).
评论